Study on Nivolumab and Ipilimumab or Chemotherapy for Untreated Inoperable or Metastatic Urothelial Cancer

Sponsor: Bristol-Myers Squibb

Sponsor score: 60

ClinicalTrials ID:NCT03036098

This clinical trial is testing whether the immunotherapy drugs nivolumab and ipilimumab, alone or with standard chemotherapy, are more effective than chemotherapy alone in treating patients with advanced urothelial cancer that cannot be surgically removed.

Patient Parameters

Program Overview

The aim of this study is to find out if using the immunotherapy drug nivolumab, either with another immunotherapy drug called ipilimumab or with standard chemotherapy, works better than just using chemotherapy alone for treating patients with advanced urothelial cancer that cannot be operated on or has spread to other parts of the body.

Eligibility Criteria

Inclusion Criteria

  • Have advanced urothelial cancer that cannot be removed by surgery, affecting areas like the kidney, bladder, or urethra.
  • Have not received any chemotherapy for this advanced cancer before.
  • Be in good overall health, with a performance status score of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
  • Agree to use effective contraception methods if applicable.

Exclusion Criteria

  • Have cancer that can be treated with local therapy aimed at curing it.
  • Have any serious or uncontrolled medical conditions that could increase risks or affect the study results.
  • Have previously been treated with certain types of immunotherapy drugs targeting specific immune pathways.
  • Other specific criteria as defined by the study protocol.

Locations

FACILITYZIPCITYSTATE
Local Institution - 000199503AnchorageAlaska
Local Institution - 011593703FresnoCalifornia
St Joseph Heritage Healthcare95403Santa RosaCalifornia
Local Institution - 005133486Boca RatonFlorida
Local Institution - 008733308Fort LauderdaleFlorida
Local Institution - 006232256JacksonvilleFlorida
Local Institution - 000430607AthensGeorgia
Local Institution - 003331792ThomasvilleGeorgia
Local Institution - 004660612ChicagoIllinois
Local Institution - 011770121New OrleansLouisiana

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.